Welcome to our dedicated page for Ideaya Biosciences news (Ticker: IDYA), a resource for investors and traders seeking the latest updates and insights on Ideaya Biosciences stock.
IDEAYA Biosciences, Inc. (NASDAQ: IDYA) is a precision medicine oncology company whose news flow is driven by clinical trial milestones, regulatory interactions, strategic collaborations, and corporate updates. The company regularly issues press releases detailing progress across a deep pipeline of targeted small molecules and antibody-drug conjugates (ADCs) for molecularly defined solid tumors.
News related to IDYA often highlights developments in its lead program darovasertib, an oral protein kinase C inhibitor in clinical trials for uveal melanoma. Updates include enrollment milestones, progression-free survival and overall survival data from trials such as OptimUM-01 and OptimUM-02 in metastatic uveal melanoma, and neoadjuvant data from OptimUM-09 and the Phase 3 OptimUM-10 trial in primary uveal melanoma. IDEAYA also reports on regulatory designations for darovasertib and its collaboration with Servier for rights outside the United States.
Investors following IDEAYA news will see frequent announcements on its broader pipeline, including IDE397 for MTAP-deleted urothelial cancer and NSCLC, IDE849 for small cell lung cancer and neuroendocrine carcinomas, IDE161 as a PARG inhibitor for ADC combinations, IDE034 as a bispecific B7H3/PTK7 TOP1 ADC, IDE574 as a KAT6/7 dual inhibitor, and IDE892 as a PRMT5 inhibitor. Press releases cover IND submissions and clearances, Phase 1 and Phase 2 data readouts, and plans for upcoming medical conference presentations.
IDYA news also includes financial results, cash runway commentary, licensing transactions such as the Servier darovasertib agreement, and governance or compensation updates reported via SEC filings and corporate press releases. Tracking this news stream provides insight into IDEAYA’s clinical progress, partnering activity, and evolving precision oncology strategy.
IDEAYA (Nasdaq: IDYA) reported Q1 2026 results and a business update highlighting a pivotal clinical win and strong liquidity. The Phase 2/3 OptimUM-02 darovasertib combination met its primary endpoint (HR 0.42; median PFS 6.9 vs 3.1 months).
The company plans an NDA submission in H2 2026 under FDA RTOR, multiple H2 2026 data readouts, and reported $972.9M cash as of March 31, 2026 with runway into 2030.
IDEAYA Biosciences (NASDAQ: IDYA) granted non-qualified stock options to five newly hired employees on April 30, 2026 under its 2023 Inducement Plan. An aggregate of 237,800 options were granted at an exercise price of $29.10 per share, equal to the April 30 closing price.
The options have a 10-year term and vest over four years (25% after one year, then monthly over three years), subject to continued service.
IDEAYA (NASDAQ: IDYA) will initiate an FDA RTOR submission for darovasertib plus crizotinib in first-line HLA*A2-negative metastatic uveal melanoma following positive Phase 2/3 OptimUM-02 topline results. The trial met its primary endpoint: PFS 6.9 vs 3.1 months (HR 0.42; 95% CI 0.30-0.59; p<0.0001).
IDEAYA plans the first RTOR pre-submission in May and expects NDA completion in H2 2026; full results to be presented at ASCO 2026.
IDEAYA Biosciences (Nasdaq: IDYA) will present complete Phase 2/3 registrational data from the OptimUM-02 trial of darovasertib plus crizotinib in 1L HLA*A2-negative metastatic uveal melanoma at ASCO 2026.
The late-breaking oral presentation (LBA9503) is scheduled for June 1, 2026, 8-11AM CDT in the Melanoma/Skin Cancers session; Dr. Marlana Orloff will present additional data not included in prior topline disclosure.
IDEAYA (NASDAQ: IDYA) and Servier reported positive topline results from the Phase 2/3 OptimUM-02 trial of darovasertib plus crizotinib in first-line HLA-A*02:01-negative metastatic uveal melanoma. The combination improved median PFS to 6.9 months vs 3.1 months (HR 0.42; 95% CI 0.30-0.59; p<0.0001) and ORR to 37.1% vs 5.8% (p<0.0001), including five complete responses. Median DOR was 6.8 months. Safety was manageable with known adverse events; serious treatment-related events were single-digit percent. An NDA submission is planned for H2 2026 and full data will be presented at a major 2026 medical conference.
IDEAYA (NASDAQ: IDYA) will release topline results from the Phase 2/3 OptimUM-02 trial on Monday, April 13, 2026 at 8:00 a.m. ET. The trial evaluates darovasertib plus crizotinib in first-line HLA*A2-negative metastatic uveal melanoma.
A joint IDEAYA and Servier pre-market release will be followed by a conference call and webcast; a replay will be available on IDEAYA's website for 30 days.
IDEAYA (NASDAQ: IDYA) announced first‑patient‑in for a Phase 1 dose‑escalation trial of IDE574, a potential first‑in‑class oral dual inhibitor of KAT6 and KAT7, on April 6, 2026. The trial will evaluate safety, pharmacokinetics, and monotherapy efficacy in solid tumors including breast, prostate, colorectal, and lung cancer.
IDE574 shows single‑digit to low‑teen nanomolar cellular potency, ~350‑to‑2,000x selectivity versus KAT5/KAT8, and superior preclinical monotherapy durability versus KAT6 selective inhibitors; a preclinical profile will be presented at AACR 2026.
IDEAYA (NASDAQ: IDYA) announced first-patient-in (FPI) for a Phase 1 combination study of IDE849 (DLL3-targeting TOP1 ADC) plus IDE161 (PARG inhibitor) in DLL3-upregulated solid tumors, including SCLC, NETs, NECs, and melanoma.
The ongoing global IDE849 Phase 1 program is evaluating 3.5 mg/kg IV Q3W in dose escalation and a 2.4 mg/kg IV Q3W expansion cohort where multiple RECIST v1.1 partial responses were observed; a clinical data update is planned for H2 2026.
IDEAYA Biosciences (NASDAQ: IDYA) announced inducement grants on March 26, 2026 of non-qualified stock options totaling 49,000 shares to two newly hired employees under the 2023 Inducement Plan.
The options carry an exercise price of $32.09 (closing price on grant date), a 10-year term, and vest over four years (25% after one year, then monthly over three years), subject to continued service.
IDEAYA Biosciences (NASDAQ: IDYA) announced investor events and updated timing guidance for topline results from the Phase 2/3 OptimUM-02 trial in first-line HLA-A2*-negative metastatic uveal melanoma. The company projects a database lock in the first half of April, followed by topline data analysis and a live investor webcast.
Management will host live webcasts and fireside chats at Bank of America Merrill Lynch (May 12, 2026) and Stifel Targeted Oncology Virtual Forum (May 19, 2026); replays will be available for 30 days and preregistration will be provided on IDEAYA's investor events page.